Orthofix expects Medicare rates for bone stimulators to return to pre-May 18 levels
On July 1, 2026, the Centers for Medicare & Medicaid Services withdrew billing and fee schedule changes that followed the FDA's April 16, 2026 reclassification of non-invasive bone growth stimulators. Orthofix now expects average Medicare reimbursement for the affected codes to return to the rates in effect before May 18, 2026. The filing gives no dollar figures for the expected impact.
Key points
- FDA final order on April 16, 2026 reclassified non-invasive bone growth stimulators from Class III to Class II devices.
- CMS changes to billing and Medicare fee schedule treatment applied to HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026.
- On July 1, 2026, CMS withdrew those changes and directed that devices furnished on or after May 18, 2026 be paid as before the reclassification.
- Orthofix expects average Medicare reimbursement for these codes to return to pre-May 18, 2026 rates; no dollar amounts were disclosed.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.